Matt Patterson is the Executive Chair of Remix Therapeutics. He was the co-founder of Audentes Therapeutics, now Astellas Gene Therapies, and previously served in the roles of Strategic Advisor and Chief Executive Officer from the Company’s inception in November 2012 until January 2020. Mr. Patterson was also Chairman of the Board of Directors and formerly served as President until May 2018. He has more than 25 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.
In addition to his role at Remix Therapeutics, Mr. Patterson currently serves as Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, and Vor Biopharma. He is also a member of the Board of Directors for Homology Medicines. Mr. Patterson received his Bachelor’s degree in Biochemistry from Bowdoin College.